Market Currents
Salix Pharmaceuticals (SLXP) +8.4% premarket after saying that an FDA advisory panel supports...
-
Thursday, November 17, 2011, 9:29 AM ETSalix Pharmaceuticals (SLXP) +8.4% premarket after saying that an FDA advisory panel supports its proposed trial to test repeat treatment cycles of its Xifaxan tablets for irritable bowel syndrome. (earlier)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
